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Summary
Background: The study of determinants of asthma is a subject of much interest
currently, especially the pharmacogenetic aspects of asthma management. Genetic
polymorphisms affecting amino-acids at positions 16 and 27 within b2-adrenoceptor
(b2AR) gene have been implicated in the asthma phenotypes and influence on the
variability observed in response to use of bronchodilator agents used in the
treatment of asthma. Whether these polymorphisms alter the bronchoprotectionee front matter & 2005
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currently working at th
in.response to b2-agonist treatment in Spanish asthmatic population is unknown. The
aim of this study was to investigate whether genetic polymorphisms within b2AR
gene modulate the clinical outcomes of the individual response to b2-agonist therapy
and the development of desensitization in Spanish asthmatic patients.
Methods: In a prospective, case-control study were included 80 asthmatic patients.
Based on the standard criteria, patients were classified into two groups: patients
with tachyphylaxis and good responders to b2-agonist therapy. DNA samples were
genotyped for the Arg16Gly and Glu27Gln alleles within the b2AR gene as well as in 64
control samples from blood donors.
Results: Arg16 allele was slightly more frequent within the group with tachyphylaxis
(P ¼ 0:039), whereas Gly16 allele carriers were overrepresented within the group of
good responders (59.7%, P ¼ 0:028). On the other hand, the allele frequency of Gln27Published by Elsevier Ltd.
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(P ¼ 0:010 and 0:049, respectively) and Glu27 allele carriers were overrepresented
within the group of good responders (P ¼ 0:026). The Arg16 and Gln27 alleles were in
strong linkage disequilibrium across this locus, resulting in the occurrence of disease
haplotype.
Conclusions: The predisposition to develop tachyphylaxis in our population seems to
be linked to the Arg16 and Gln27 alleles and to the Arg16/Gln27 risk haplotype
(positive association between the presence of the Arg16 and Gln27 alleles and
tachyphylaxis). The Arg16 allele is perhaps overrepresented due to the strong linkage
disequilibrium between both polymorphisms. The presence of the Glu27 allele seems
to be a protective factor against tachyphylaxis in this cohort study.
& 2005 Published by Elsevier Ltd.Introduction
Beta2-adrenergic receptor (b2AR) is a cell surface
protein expressed on many lung cell types relevant
to asthma, i.e. airway epithelial cells, bronchial
smooth muscle, pre-synaptic nerve terminals and
eosinophils. b2AR is coupled to a G-protein that
activates adenylate-cyclase resulting in the forma-
tion of AMPc which, as a second messenger,
activates protein-kinases that mediate different
responses on different cell types.
Beta2-adrenoceptor agonists are used by virtually
all patients as rescue bronchodilator agents and
recommended as first-line therapy for the relief of
bronchoconstriction in patients with asthma due to
its protective effects against direct and indirect
bronchoconstrictor stimuli shown by short- and
long-acting b2-agonists. Regular treatment with
both short- and long-acting b2-agonists may result
in b2AR desensitization, a phenomenon termed
‘‘tachyphylaxis’’ which is associated to the loss of
functional antagonism to bronchoconstrictor stimu-
li, although the relevance of this phenomenon in
terms of long-term asthma control remains unclear.
There has been a debate on whether a subgroup
of asthmatic patients does not benefit from regular
b2-agonist therapy. One potential source of the
individual variability to b2-agonist response could
be DNA sequence variations (polymorphisms) within
b2AR gene. Within the coding region of the human
b2-adrenoceptor gene itself, until now, nine SNPs
have been identified,1 five of which are degener-
ate. Non-degenerate polymorphisms result in single
amino acid substitutions in codon 16 (Arg16–Gly), 27
(Gln27–Glu), 34 (Val34–Met), and 164 (Thr164–Ile).
Amino-acids 16 and 27 lie in the extracellular
domain and amino-acids 34 and 164 in the trans-
membrane spanning regions. The relative frequen-
cies of these polymorphisms are similar in normal
and asthmatic population and this does not seem to
determine the development of the asthmaticphenotype, although it may contribute to its
modification.2
Several recent studies have related both Arg16–
Gly and Gln27–Glu polymorphisms to different
clinical and analytical data. Taking into account,
as expected, that there is a strong linkage
disequilibrium between these polymorphisms, it is
difficult to assign an effect to a single allele in
association studies. Gly16 has been associated
with nocturnal asthma,3 lower response to inhaled
b2-agonists in children and increased bronchial
hyperresponsiveness (BHR) to histamine. At codon
27, the Gln polymorphism is associated with
elevated IgE levels while the Glu27 allele is
associated with lower airways hyperreactivity to
methacoline in asthmatics families.4 In a recent
study, Joos et al.5 found a negative association
(protective effect) between heterozygosity at
position 27 and an accelerated rate of decline in
lung function in smokers.
Homozygous individuals for Arg16 showed an
increased response to albuterol both in asthmatic
and non-asthmatic children and the effect was
independent of baseline lung function and ethnic
origin.6 Furthermore, ‘‘in vitro’’ studies showed
that Gly16Arg and Glu27Gln polymorphisms mark-
edly altered the agonist promoted receptor down-
regulation and functional desensitization of b2AR.
7
The phenotypic consequences of a given single
polymorphism could be at the same time modified
by interactions with other polymorphisms in the
promoter or coding region.8 So, the variability of
the response to inhaled b2-agonists could be better
predicted by b2AR extended haplotypes.
Our hypothesis was that the polymorphisms
within b2AR gene could modulate the bronchodi-
lator response to inhaled b2-agonists by inducing
tachyphylaxis in the Spanish asthmatic population.
The aim of this study is to compare the relative
frequency of the two main b2AR polymorphisms
between asthmatic patients and control subjects
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combinations of these alleles and b2AR haplotypes
with the clinical outcomes of the response to
inhaled b2-agonists use and the development of
tachyphylaxis.Methods
Subjects
The patients were enrolled into a prospective,
case-control, randomized, study design. Eighty
patients (39 males and 41 females) who had an
established diagnosis of stable mild-to-moderate
persistent asthma. All patients were participants in
the Allergy Unit (University Hospital Pı´o del Rio
Hortega, Valladolid, Spain) (mean age: 29.9 year;
range 14–64 years). All cases showed serum IgE
levels above 100 IU/ml and a positive skin prick test
for at least one pneumoallergen.
All patients included in this study had been
diagnosed as having atopic asthma since at least
past six months. Patients were considered to be
atopic if they had at least one skin test measuring
3mm or more in diameter.
Data confirming obstruction included increased
residual volume and airway resistance, uneven
distribution of ventilation and decrease of FEV1
according to American Thoracic Society (ATS)
criteria.9 Reversibility of airway obstruction in
response to administration of bronchodilator aero-
sol (salbutamol 400 mg) was measured following
standard method from ATS.9,10 A positive reversi-
bility test was defined by an increase of FEV1 higher
than 15% after inhalation of 400 mg of salbutamol
and measured as:reversibility ¼ highest FEV1 after salbutamol highest FEV1 before salbutamol
highest FEV1 before salbutamol
 100.Tachyphylaxis was defined as an absence of
response to inhalation of short-acting b2-agonists
during a period of three months and measured in at
least four occasions, and a lack of b2-agonists
mediated bronchoprotection on bronchial respon-
siveness induced by bronchial challenge with
specific allergen performed by using the Cockcroft
technique.11 Based on these criteria, patients were
classified in two groups:
Group with tachyphylaxis: Twenty-three out of
80 (28.8%) (10 males and 13 females) (mean
age:31.2 year; range 14–59 years) with tachyphy-
laxis to inhaled b2-agonists. None patients receivedinhaled steroid therapy in order to avoid con-
founded results in the reversibility to bronchodi-
lator.
Group of good responders: Fifty-seven patients
(29 males and 28 females) (mean age: 29.4 year;
range 15–64 years) with good response to inhaled
b2-agonists use. Steroid therapy was not needed in
this group of patients.
b2-agonists are used on demand and the dosage is
adjusted by the patients themselves, with a limit of
6 puffs per day. At the end of the study, the group
of patients with tachyphylaxis were taking a higher
dose of b2-agonists. The mean number of daily
puffs of the bronchodilator in the ‘‘good respon-
der’’ group was 2 puffs/bid, while patients suffer-
ing from tachyphylaxis this was 6 puffs/bid.
Patients were excluded of study if they had been
treated with oral corticosteroids in the past
6 months or had a history of recent respiratory
tract infection within the past 3 months, or had
smoked cigarettes within the previous 12 months.
Sixty-four samples from blood donors were
studied to assess the frequency of the b2AR alleles
in our population. Asthma patients cannot be blood
donors in our Hospital. Individuals from both groups
(asthma patients and controls) were white Cauca-
sian Spanish and did not include individuals from
different ethnic background. All of the patients
gave written informed consent for the study, which
was approved by the Valladolid University Hospital
Committee for Medical Research Ethics.
Genotyping methods
Genomic DNA was extracted from whole peripheral
blood samples using standard techniques. Genotyp-
ing of the polymorphisms at positions 16 and 27within b2AR gene was performed by a combination
of primer-induced restriction site assay for Arg16Gly
polymorphism and restriction fragment assay for
Gln27Glu polymorphism as previously described
elsewhere.6
The b2AR-27 alleles were typed using enzyme
BseXI (Fermentass), an isoschizomer of Bbv I. In
this case the PCR amplimers were digested at 65 1C
for 3 h.
The products of each PCR reaction were resolved
by electrophoresis on 3% agarose gels stained with
ethidium bromide. Template-free and known geno-
type controls were included in each experiment.
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phenotypes by two independent observers. The
samples were re-genotyped if there was any
disagreement concerning the genotype.
Statistical analysis
The results are presented as haplotype and allele
frequencies for both asthmatic (tachyphylaxis and
good responders) groups. The differences in haplo-
types and allele frequency between the two groups
were assessed by Pearson’s w2 tests for 2 2
contingency tables as previously described.12 All
tests were performed using the JMP Statistics
software package (SAS Institute Inc). A P value of
o0.05 was considered to be statistically signifi-
cant. All values are expressed as mean (SE).
Haplotypes frequencies were estimated using the
expectation maximisation (EM) algorithm since
haplotypes could not be discerned directly from
double heterozygotes. The Arlequin software pack-
age was used to perform these estimations, to test
for linkage disequilibrium, and for Hardy-Weinberg
equilibrium. The analysis of the haplotypes defined
by the two b2AR polymorphisms was performed by
using the Haplo-Score Package.13Results
The allele frequencies found in our Spanish
population were 0.51 for Gly16 and 0.63 for Gln27,
thus the results were similar to those previouslyTable 1 Distribution of the genotypes identified among
CODON 16
FMA Genotypes
Population# Arg16 Arg/Arg Arg/Gly G
Asthmatic patients 69/160 13 43 24
(n ¼ 80) (43.1%) (16.2%) (53.7%) (3
Tachyphylaxis 23/46 7 9 7
(n ¼ 23) (50.0%) (30.4%) (39.1%) (3
Good responders 46/114 6 34 17
(n ¼ 57) (40.4%) (10.5%) (59.7%) (2
Controls 63/128 17 29 18
(n ¼ 64) (49.3%) (26.6%) (45.3%) (2
w2 ¼ 1:064,
P ¼ 0:302+
Definition of abbreviations: Arg ¼ Arginine; Gly ¼ Glycine; Gln ¼
Number of subjects with polymorphisms at positions 16 and 27 o
FMA: frequency of the minor allele.
#Values are shown as number of subjects (%), unless otherwise
+Hardy-Weinberg equilibrium test values.reported by other authors25 for Caucasian popula-
tions.
The study of homozygous samples for at least one
polymorphism showed a strong linkage disequili-
brium (D0 ¼ 100%, Po0:000001) given that 75.0% of
Arg16 chromosomes carried the Gln27 allele; and
this linkage was also found both in asthmatic
patients (73.9%) and controls (76.1%) without
significant statistical differences.
Single-locus analysis
Allele frequencies (Table 1) found were almost
similar in asthmatic patients and controls for both
Arg16 (43.1% and 49.3%, w2 ¼ 1:064; P ¼ 0:302; res-
pectively) and Gln27 (58.1% and 62.5%, w2 ¼ 0:739;
P ¼ 0:390; respectively).
Genotypic frequencies of Arg16Gly and Gln27Glu
polymorphisms were in Hardy-Weinberg equilibrium
and did not show statistically significance differ-
ences between both groups.
Individuals carrying the Gly16 allele were more
frequent within the group of good responders than
in the group with tachyphylaxis (59.7% vs. 39.1%,
respectively; w2 ¼ 6:482; P ¼ 0:028) and this is
caused by the increased number of heterozygous
Arg16Gly (n ¼ 34). In fact, 51/57 (89.5%) patients
without tachyphylaxis carrying the Gly16 allele
(Table 1).
Otherwise, the Gln27 allele was overrepresented
within group of patients with tachyphylaxis when
allele frequencies were compared with good re-
sponders (73.9% vs. 51.8%, respectively; w2 ¼ 9:509,the groups studied.
CODON 27
FMA Genotypes
ly/Gly Glu27 Gln/Gln Gln/Glu Glu/Glu
67/160 27 39 14
0.1%) (41.9%) (33.8%) (48.7%) (17.5%)
12/46 12 10 1
0.5%) (26.1%) (52.2%) (43.5%) (4.3%)
55/114 15 29 13
9.8%) (48.2%) (26.3%) (50.9%) (22.8%)
48/128 30 20 14
8.1%) (37.5%) (46.9%) (31.2%) (21.9%)
w2 ¼ 0:739,
P ¼ 0:390+
Glutamine; Glu ¼ Glutamic acid.
f b2AR gene.
indicated.
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within group of tachyphylaxis (95.7%) while Glu27
allele carriers were more frequent within group of
good responders (73.7%). Fourteen asthmatic pa-
tients were Glu27/Glu27 homozygous (17.5%), only
one of them was identified within the group with
tachyphylaxis (4.3%) (Fig. 1).
Haplotype analysis
The analysis of the distribution of b2AR haplotypes
within the stratified population showed a globalTable 2 Observed frequencies of the b2AR gene haploty
asthmatic patients with tachyphylaxis and good responder
b2AR Gene haplotypes Good responders (n ¼ 57)
n (%)
1–1 1 1.8
1–2 4 7.0
1–3 10 17.5
1–4 +2–3 19 33.3
2–2 1 1.8
2–4 5 8.8
3–3 4 7.0
3–4 6 10.5
4–4 7 12.3
Nomenclature of the b2AR gene haplotypes determined (used):
Gln27, Allele 4: Gly16/Glu27.
The linkage disequilibrium phase is unknown in double hetero
Arg16Gly
Arg16GlyArg/Arg Gly/Gly
tachyphylaxis
30.4% 39.1% 30.5%
no tachyphylaxis
10.5% 59.7% 29.8%
Gln27Glu
Gln/Gln Gln/Glu Glu/Glu
tachyphylaxis
no tachyphylaxis
52.2% 43.5%
4.3%
26.3% 50.9% 22.8%
Figure 1 Gly16 and Glu27 alleles carriers were over-
represented within the group of patients with no tachy-
phylaxis to b2-agonists (P ¼ 0:028 and 0:026, respectively).statistical (P ¼ 0:078). The Arg16/Gln27 haplotype
was more frequent within the group of patients
with tachyphylaxis (26.1%, P ¼ 0:025). Six out of 23
(26.1%) patients with tachyphylaxis and 1/57 (1.8%)
good responders were homozygous for this haplo-
type (Table 2). Between good responders, the most
frequent haplotype was Gly16/Glu27, but was not
significant statistical (33.3%, P ¼ 0:087). In Fig. 2,
the frequencies (%) of the four haplotypes both in
good responders vs. patients with tachyphylaxis are
shown. Nineteen good responders and 4 patients
with tachyphylaxis were double heterozygous and
the linkage phase of both polymorphisms could not
be settled (Table 2).Discussion
b2AR gene maps within the chromosomal region
5q31–33.14 This region contains many candidate
genes which may be involved in the pathogenesis of
asthma and atopy. Several studies have failed to
demonstrate any relationship between b2AR alleles
and predisposition to asthma.15
The results of the present study showed that the
allele frequencies were almost similar in asthmatic
patients and in controls. The distribution of the
genotypes were in Hardy-Weinberg equilibrium and
not significant differences were found between
both groups. These data agree with previous
reports7,15 and confirm the absence of association
between b2AR alleles and susceptibility to
asthma.
The dosage of b2-agonists varies depending on
demand by each patient. As explained above, at
the end of the study, patients with tachyphylaxispes for polymorphisms at positions 16 and 27 among
s to b2-agonist therapy.
Tachyphylaxis (n ¼ 23)
n (%)
6 26.1
1 4.3
4 17.4
4 17.4
0 0
1 4.3
1 4.3
6 26.1
0 0
Allele 1: Arg16/Gln27, Allele 2: Arg16/Glu27 , Allele 3: Gly16/
zygous patients.
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Figure 2 Haplotype frequencies in b2AR genes. Linkage
phase of the studied polymorphisms could not be settled
in 38 chromosomes from patients with good response and
in 8 chromosomes from patients with tachyphylaxis. P ¼
0:025 Student’s test.
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Although it could be suggested that the tachyphy-
laxis to b2-agonists may be due to the dosage taken
by the patients, we think that this is actually the
consequence of the progressive loss of sensitivity to
b2-agonists.
It is noteworthy to mention the clear difference
found between asthmatic patients and good re-
sponse and those with tachyphylaxis to b2-agonists.
The risk of tachyphylaxis was higher in Gln27 allele
carrying patients. Forty-four out of 57 patients
(77.2%) within the group of good responders and
22/23 (95.7%) individuals within the group with
tachyphylaxis carried at least one Gln27 allele
(P ¼ 0:049). This risk seems to be higher in
homozygous (Gln27/Gln27) since 12/23 (52.2%)
patients with tachyphylaxis and 15/57 (26.3%) good
responders were Gln27 homozygous (52.2% vs.
26.3%, P ¼ 0:027).
Our results suggest that the predisposition to
desensitization in our population could be asso-
ciated to both Arg16 and Gln27 variants, although
the later polymorphism (Gln27) seems to play a
more important role, bearing in mind that it is
difficult to assign a causative role to any single
allele due to strong linkage disequilibrium exists
between these promoter polymorphisms (and those
within the coding region or the immediate region of
the b2AR gene), resulting in the occurrence of
several common haplotypes.
In fact, in our study, the risk of developing
tachyphylaxis seems to be linked to haplotype
Arg16/Gln27, in agreement to Drysdale et al.8 which
performed a comprehensive survey of b2AR haplo-types and showed that the Arg16/Gly16 and Gln27/
Glu27 polymorphisms are sufficient to distinguish
the three common haplotypes in white subjects.
Another seven haplotypes exist in the white
population but they are all rare and the combined
frequency of these haplotypes is only 5.5%. It is
therefore unlikely that additional haplotype data
would substantially change our results, although
the global statistic is only indicative of a weak
association. This result suggests than it would be
desirable to develop simple but robust molecular
methods to determine the haplotype structure of
Spanish asthmatic patients.
Our study is discordant with a previous study that
reported linkage between predisposition to bronch-
odilator desensitization and alleles Gly16 and
Glu27.16 The different findings could be explained
since this study is quantitative measured as (%) of
desensitization and carried out in 22 asthma
patients. Moreover, most patients were receiving
steroid therapy which could be a modifier of the
response to b2-agonists.
According to these results, it is clear that variants
within the b2AR gene could modify the response to
b2-agonist therapy in our Spanish population.
Although it is difficult to explain the different
behaviour of the variants at codons 16 and 27, our
data corroborates a previous study of the functional
effects in lung mast cells where Gly16 and Glu27
isoforms within b2AR gene were resistant to
agonist-induced desensitization, as expressed by
isoproterenol-induced inhibition of histamine re-
lease. Here the polymorphism at position 27 seems
to play the most important role.17
The role of b2-adrenoceptor regulation in asthma
is unclear yet. While tachyphylaxis to the bronch-
odilator effects of b2-agonists occurs in non-
asthmatic individuals, it has been difficult to
demonstrate in asthmatics.18–22 However, toler-
ance to the broncho-protective effects of b2-
agonists in asthma has been demonstrated.23–25
Thus, the mechanisms of b2-adrenoceptor regula-
tion in asthma appear to differ between cell types
and may be altered by disease states.26 It has been
reported that asthmatic subjects homozygous for
Gly16 demonstrate greater tachyphylaxis to the
long-acting b2-agonist formoterol.
16
In summary, this is the first report to address the
possible effect of these b2AR gene polymorphisms on
the response to regular use of b2-agonists in the
Spanish asthmatic population. Nevertheless, results
of the associations shown spite of the relatively small
size of the sample, are significant and they can be
therefore relevant for respiratory clinicians and
geneticists in order to make out whether a patient
will be responsive to b2-agonist treatment, or
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b2-agonist therapy, as well as to the current asthma
management guidelines, since b2-agonists represents
the first-line therapy in treatment of asthma.
Further studies involving larger patient numbers
are needed to assess the association between asthma
phenotypes and haplotypes analysis studied to date,
the role played by b2AR isoforms in the development
of tachyphylaxis to b2-agonists, as well as to define
the most accurate therapy for the individual asthma
patient in our Spanish population. Up to date, it is
also truth that many questions related to the risk of
desensitization remain unclear.Acknowledgements
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